FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. META
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
(NASDAQ: FBLG) Delayed: 0.75 -0.06 (7.41%)
Previous Close $0.81    52 Week High $ 
Open $0.82    52 Week Low $ 
Day High $0.84    P/E N/A 
Day Low $0.75    EPS $ 
Volume 247,182